期刊文献+

烟酸对维持性血液透析中高磷血症患者的影响

Effect of nicotinic acid on hyperphosphatemia in maintenance hemodialysis patients
原文传递
导出
摘要 目的 分析烟酸对维持性血液透析(MHD)中高磷血症患者的影响.方法 选择病情稳定且存在常规治疗方法不能控制高磷血症的MHD患者26例,口服烟酸20周,观察患者治疗前后血钙、超敏C反应蛋白(hs-CRP)、白蛋白(ALB)、天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转移酶(GGT)、总胆红素(TBIL)、直接胆红素(DBIL)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)、全段甲状旁腺激素(iPTH)、血红蛋白、血小板计数等的变化.结果 2例患者因口服烟酸2周时出现皮肤瘙痒及腹泻,退出本研究.余24例患者治疗后血磷、钙磷乘积较治疗前明显降低[(1.49±0.19) mmol/L比(2.13±0.16) mmol/L、(4.40±0.49)mmol2/L2比(5.45±0.36) mmol2/L2],HDL-C较治疗前明显升高[(1.45±0.14) mmol/L比(1.18±0.15) mmol/L],差异均有统计学意义(P<0.05).治疗前后血钙、iPTH、LDL-C、TG、TC、ALB、AST、ALT、GGT、TBIL、DBIL、hs-CRP、血小板计数、血红蛋白比较差异均无统计学意义(P>0.05).结论 烟酸治疗MHD患者既可以降低血磷,又可以升高HDL-C,降低心血管并发症的发生风险,这为MHD患者高磷血症的控制提供了一条新途径. Objective To assess the effect of nicotinic acid on hyperphosphatemia in maintenance hemodialysis (MHD) patients.Methods Twenty-six MHD patients with stable disease condition and hyperphosphatemia that could not be successfully controlled by conventional methods were selected.All patients were treated with oral nicotinic acid for 20 weeks.The changes of serum calcium,high sensitivity Creactive protein (hs-CRP),albumin (ALB),aspartate aminotransferase (AST),alanine aminotransferase (ALT),gamma-glutmyltransferase (GGT),total bilirubin (TBIL),derect bilirubin (DBIL),high density lipoprotein cholesferol (HDL-C),low density lipoprotein cholesferol (LDL-C),triacylglycerol (TG),total cholesterol (TC),intact parathyroid hormone,hemoglobin,platelet count,etc were observed before and after treatment.Results Two patients withdrew from this study because.of pruritus and diarrhea after two weeks of oral nicotinic acid.In 24 cases,compared with that before treatment,the serum phosphate,calcium-phosphorus product was decreased [(1.49 ± 0.19) mmol/L vs.(2.13 ± 0.16) mmol/L,(4.40 ± 0.49)mmol2/L2 vs.(5.45 ± 0.36) mmol2/L2] and HDL-C was increased [(1.45 ± 0.14) mmol/L vs.(1.18 ± 0.15)mmol/L] after treatment,and there was significant difference (P 〈 0.05).There was no significant difference in the serum calcium,iPTH,LDL-C,TG,TC,ALB,AST,ALT,GGT,TBIL,DBIL,hs-CRP,platelet count,hemoglobin between before and after treatment (P 〉 0.05).Conclusions Nicotinic acid is effective as all adjuvant measure in control of hyperphosphatemia in patients on MHD and can increase HDL-C.It provides a new approach for the treatment of hyperphosphatemia.
出处 《中国医师进修杂志》 2013年第34期7-9,共3页 Chinese Journal of Postgraduates of Medicine
关键词 肾透析 尼克酸 高磷血症 Renal dialysis Niacin Hyperphosphatemia
  • 相关文献

参考文献11

  • 1Checheri~ IA,Smarandache D,David C,et al. Vascular calcifications in chronic kidney disease--clinical management. Rom J Morphal Embryo1,2012,53( 1 ) :7-13. 被引量:1
  • 2秦纪平,张翀,常娟,汤志奇,茅宇烽,施莲珍.高磷血症维持性血液透析患者的临床分析[J].现代生物医学进展,2011,11(22):4276-4278. 被引量:6
  • 3Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med,2010,362(14) : 1312-1324. 被引量:1
  • 4Raggi P,Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol, 2008,3 (3) : 836-843. 被引量:1
  • 5张景红,宦红娣.维持性血液透析患者高磷血症的控制[J].中国血液净化,2009,8(10):533-535. 被引量:25
  • 6Navaneethan SD, Palmer SC, Craig JC,et al. Benefits and harms of phosphate binders in CKD:a systematic review of randomized controlled trials. Am J Kidney Dis, 2009,54 ( 4 ) : 619-637. 被引量:1
  • 7Sampathkumar K. Niacin and analogs for phosphate control in dialysis--perspective from a developing country. Int Urol Nephrel, 2009,41(4) :913-918. 被引量:1
  • 8Foley RN, Collins A J, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Sac Nephrol, 2009,20 ( 2 ) : 397 -404. 被引量:1
  • 9Hutchison A J, Barnett ME, Krause R J, et al. Lanthanum carbonate treatment, for up to 6 years,is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol, 2009,71 (3) : 286-295. 被引量:1
  • 10Delanaye P,Weekers L,Krzesinski JM. Diarrhea induced by high doses of nicotinamide in dialysis patients. Kidney Int,2006,69 (10) : 1914. 被引量:1

二级参考文献21

  • 1唐万欣,付平,杨宁,周莉,黄颂敏,许国章.高通量透析联合大剂量促红细胞生成素治疗尿毒症贫血的临床观察[J].新医学,2006,37(2):81-83. 被引量:11
  • 2张怡玲,田丽,张军莉.透析患者血磷状态的观察[J].中华肾脏病杂志,2006,22(1):58-58. 被引量:6
  • 3Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis[J].J Am Soc Nephrol, 2004, 15:2208-2218. 被引量:1
  • 4Itoh N, Ornitz DM. Evolution of the FGF and FGFR gene families[J]. Trends Genet, 2004, 20:563-569. 被引量:1
  • 5Yan X, Yokote H, Jing Let al. Fibroblast growth factor 23 reduces expression of type-IIa Na+/Pi co-transporter by signaling through a receptor function ally distinct from the known FGFRs in opossum kidney cells[J]. Genes Cells, 2005,10:489-502. 被引量:1
  • 6Kazama JJ, Gejyo F, Shigematsu T, et al. Role of circulating fihroblast growth factor 23 in the development of secondary hyperparathyroidism[J]. Ther Apher Dial, 2005, 9:328-330. 被引量:1
  • 7Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease[J].J Am Soc Nephrol, 2004,16: 520-528. 被引量:1
  • 8Forley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of calcium and phosphate metabolism in chronic renal disease [J].Am J Kidney Dis, 1998,32: S112-S119. 被引量:1
  • 9Lindsay RM, Alhejaili F, Nesrallah G, et al. Calcium and phosphate balance with quotidian hemodialysis[J].AmJ Kidney Dis, 2003,42 (Suppl 1): 24-29. 被引量:1
  • 10Hutchison, Alastair J. Improving phosphate-binder therapy, a way forward[J]. Nephrol dial Transplant, 2004,19(Suppl 1): 19-24. 被引量:1

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部